AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients

References

• Grillo-Lcipez AJ, Dallaire BK, McClure A et al. Monoclonal antibodies: a new era in the treatment of non-Hodgkin's Lymphoma. Curr. Pharma. Biotechnot 2, 301–311 (2001). Up-to-date review of this important area.
   Google Scholar
• Grillo-Lcipez AJ. The important role of monoclonal antibodies in the treatment of non-Hodgkin's Lymphomas. Oncology Spectrums 2(10), 700–705 (2001).
   Google Scholar
• Grillo-Lcipez AJ. Curative therapies for NHL: a question of time In: Monoclonal antibodies in the treatment of hematologic malignancies - a Curr. Pharma. Biotechnot 2(4), 279–280 (2001).
   Google Scholar
• ••This issue of Current Pharmaceutical Biotechnology contains nine articles representing the most comprehensive and up-to-date review of monoclonal antibodies in the treatment of hematologic malignancies.
   Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl. J. Med. 346(4), 235–242 (2002).
   Google Scholar
• ••A key article on the new therapy that hasbecome the gold standard in the treatment of DLC/NHL
   Google Scholar
• Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics 2002. CA Cancer 1 Clin. 52(1), 23–47 (2002).
   Google Scholar
• Rosenberg S, Berard C, Brown J et al. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 49,2112–2135 (1982).
   Google Scholar
• Weisdorf D, Andersen J, Glick J, Oken M. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J. Clin. Oncol. 10(6), 942–947 (1992).
   Google Scholar
• Pordock CS, Rosenberg S. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann. Intern. Med 90,10–13 (1979).
   PubMedGoogle Scholar
• Horning S, Rosenberg S. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl. J. Med. 311(23), 1471–1475 (1984).
   Google Scholar
• Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment. Sem. Hemata 25(2), 11–16 (1988).
   Google Scholar
• Liesveld J, Raubertas R, Bennett J. Treatment patterns in low-grade non-Hodkin' s lymphomas: a single institution study. Med. Fed. Oncol. 19,1-7 (1991).
   Google Scholar
• Shipp MA, Ambinder RF, Zelenetz AD. NCCN Preliminary non-Hodgkin's Lymphoma Practice Guidelines. Oncology 11(11A), 281–346 (1997).
   Google Scholar
• NCCN Practice Guidelines in Oncology, Non-Hodgkin's Lymphoma. Version 1 (2001).
   Google Scholar
• Czuczman MS, Grillo-Lcipez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric antiCD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17,268-276 (1999).
   Google Scholar
• •Original pilot study of the combination of rituximab and CHOP
   Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA et al. Progression Free Survival (PFS) after Six Years (Median) Follow-up of the First Clinical Trial of Rinndmab/CHOP Chemoimmunotherapy. Blood 98(11), Part 1,601a, 2519 (2001).
   Google Scholar
• Coiffier B, Lepage E, Herbrecht R et al. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood 96(11), 223a, 950 (2000).
   Google Scholar
• Grillo-Lcipez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab (Rituxan): Ongoing and future clinical development. Sem. Oncol. 29(1), 105–112 (2002).
   Google Scholar
• Thomas E Witzig, Leo I Gordon, Fernando Cabanillas et aZ Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's Lymphoma. J. Clin. Oncol. 20(10), 2453–2463 (2002).
   Google Scholar
• ••Report on the pivotal trial of the recentlyapproved radioimmunotherapy ibriturnomab.
   Google Scholar
• White CA, Weaver RL, Grillo-LOpez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Ann. Rev. Med. 52,125–145 (2001).
   Google Scholar
• Fisher R, Gaynor E, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl. J. Med. 328(14), 1002–1006 (1993).
   Google Scholar
• Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 19(2), 389–397 (2001).
   Google Scholar
• Czuczman MS, Fallon A, Mohr A et al. Rittudmab in combination with CHOP or fludarabine in low-grade lymphoma. Sem. Oncol. 29(1), 36–40 (2002).
   Google Scholar
• Czuczman MS, Grillo-Lcipez AJ, McLaughlin P et al. Clearing of cells bearing the bc1-2 [T(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann. Oncol. 12,109-114 (2001).
   Google Scholar
• •Discussion of bc1–2 clearance by rituximab and the importance of molecular remissions.
   Google Scholar
• Gockerman J, Gregory S, Harwood S et al. Interim efficacy results of Boocar in a large multicenter open access study. J. Clin. Oncol. (Abstract 1138) (2001).
   Google Scholar
• Kupper T. FDA Requires More Testing of Seattle-Based Corixa's Lymphoma Drug. The San Diego Union-Tribune, Knight Ridder/Tribune Business News (2002).
   Google Scholar